Bio‑Thera’s Market Decline: Stagnant Prices, Slumping Capital, and Rising Investor Skepticism
Bio‑Thera’s biotech slump: flat trading, shrinking market cap, and low liquidity reveal deeper investor erosion—why caution is key in Shanghai’s stagnant biotech sector.
3 minutes to read